Therapeutic Potential of Fingolimod on Psychological Symptoms and Cognitive Function in Neuropsychiatric and Neurological Disorders Publisher Pubmed

Summary: Can MS drugs aid brain disorders? Study finds fingolimod boosts neuroprotection via S1P receptor modulation. #Neuropsychiatric #Fingolimod

Rahmatidehkordi F^{1, 2, 3} ; Khanifar H⁴ ; Najari N^{5, 6} ; Tamtaji Z⁷ ; Talebi Taheri A^{3, 8} ; Aschner M⁹ ; Shafiee Ardestani M¹⁰ ; Mirzaei H¹¹ ; Dadgostar E^{5, 6} ; Nabavizadeh F^{1, 2} ; Tamtaji OR^{1, 2}
Source: Neurochemical Research Published:2024

Abstract

Neuropsychiatric and neurological disorders pose a significant global health burden, highlighting the need for innovative therapeutic approaches. Fingolimod (FTY720), a common drug to treat multiple sclerosis, has shown promising efficacy against various neuropsychiatric and neurological disorders. Fingolimod exerts its neuroprotective effects by targeting multiple cellular and molecular processes, such as apoptosis, oxidative stress, neuroinflammation, and autophagy. By modulating Sphingosine-1-Phosphate Receptor activity, a key regulator of immune cell trafficking and neuronal function, it also affects synaptic activity and strengthens memory formation. In the hippocampus, fingolimod decreases glutamate levels and increases GABA levels, suggesting a potential role in modulating synaptic transmission and neuronal excitability. Taken together, fingolimod has emerged as a promising neuroprotective agent for neuropsychiatric and neurological disorders. Its broad spectrum of cellular and molecular effects, including the modulation of apoptosis, oxidative stress, neuroinflammation, autophagy, and synaptic plasticity, provides a comprehensive therapeutic approach for these debilitating conditions. Further research is warranted to fully elucidate the mechanisms of action of fingolimod and optimize its use in the treatment of neuropsychiatric and neurological disorders. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.